Colorado Takes Aim at High Price of Long-Monopolized Arthritis Drug

In a groundbreaking move, Colorado is set to become the first state to impose a price cap on Enbrel, a widely used medication for treating arthritis and other inflammatory conditions. The decision comes as a response to the exorbitant costs associated with the drug, which has been shielded from competition for nearly three decades through a series of savvy patent maneuvers by its manufacturer, Amgen.Enbrel, a biologic medication, has been a top seller for Amgen since its approval in 1998. Over the years, the company has skillfully employed a range of tactics, including securing multiple patents and making strategic deals with other pharmaceutical firms, to maintain its monopoly on the drug. As a result, Enbrel has become one of the most expensive medications on the market, with a list price currently exceeding $1,000 per month's supply.The high cost of Enbrel has placed a significant burden on patients, many of whom rely on the medication to manage chronic conditions such as rheumatoid arthritis, plaque psoriasis, and ankylosing spondylitis. According to a report by the Kaiser Family Foundation, the list price of Enbrel has increased by over 400% since its introduction, far outpacing the rate of inflation.By capping the price of Enbrel, Colorado aims to make the medication more affordable for residents who are struggling to access it due to its high cost. The state's move is seen as a bold step in the effort to curb prescription drug prices, which have become a major concern for policymakers and patients alike.While Amgen has argued that its patents on Enbrel are valid and protect its intellectual property, critics contend that the company's tactics have stifled competition and driven up costs. The Colorado legislation, which is expected to take effect soon, could set a precedent for other states to follow in taking action against high-priced medications.The pharmaceutical industry has taken notice of Colorado's move, with some companies expressing concerns that government intervention in drug pricing could have unintended consequences. However, patient advocacy groups and healthcare experts have welcomed the decision, arguing that it is a necessary step to ensure that life-saving medications like Enbrel are accessible to those who need them.As the debate over drug pricing continues to unfold, Colorado's decision to cap the price of Enbrel serves as a significant test case for the role of government in regulating pharmaceutical costs. The outcome could have far-reaching implications for patients, policymakers, and the pharmaceutical industry as a whole.